Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 12/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 12/20 | 1.00 |
| ▸ | BRD4 | O60885 | 7/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 7/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.61 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | PI4KA | P42356 | 1/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.55 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.55 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.55 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.55 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.55 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29538109 | 1.00 | MAPK7 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL16065687 | 1.00 | MAPK7 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL16065728 | 0.94 | LRRK2 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL17465830 | 0.90 | LRRK2 (0.85) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL24239838 | 0.89 | MAPK7 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL29372647 | 0.89 | MAPK7 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL21784112 | 0.86 | MAPK7 (0.76) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL29596956 | 0.86 | LRRK2 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL616761 | 0.86 | LRRK2 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT | |
| SCHEMBL29389108 | 0.86 | LRRK2 (1.00) | MAPK7LRRK2BRD4DCLK1BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116173040-B | Use of XMD17109 as ARIH1 agonist | 杭州天玑济世生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-116173040-A | Use of XMD17109 as an ARIH1 agonist | 杭州天玑济世生物科技有限公司 | 2023-05-30 | — | — | CN | claimed |
| EP-4036583-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | Board of Regents, The University of Texas System (US) | 2022-08-03 | — | — | EP | claimed |
| EP-4034132-B1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA FARBER CANCER INST INC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| CN-116173040-B | Use of XMD17109 as ARIH1 agonist | 杭州天玑济世生物科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-116173040-B | Use of XMD17109 as ARIH1 agonist | 杭州天玑济世生物科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-116173040-B | Use of XMD17109 as ARIH1 agonist | 杭州天玑济世生物科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| US-11406643-B2 | Targeting kinases for the treatment of cancer metastasis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-09 | — | — | US | disclosed |
| EP-4036583-A1 | TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS | Board of Regents, The University of Texas System (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-4034132-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-20220162711-A1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZURICH (CH) | 2022-05-26 | — | — | US | disclosed |
| WO-2022078350-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| EP-3559276-B1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZUERICH (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-20220031710-A1 | USE OF ERK5 INHIBITORS FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551563-B2 | ERK5 degraders as therapeutics in cancer and inflammatory diseases | OXSR1, MAPK1, NGFR | MAPK7 30/4885LRRK2 340/4885BRD4 1128/4885 |
| US-20220031710-A1 | USE OF ERK5 INHIBITORS FOR TREATING GLIOMAS IN PEDIATRIC SUBJECTS | DOT1L, IQGAP1, EZH2 | MAPK7 133/4885LRRK2 849/4885BRD4 598/4885 |
| US-20220378919-A1 | ERK5 DEGRADERS AS THERAPEUTICS IN CANCER AND INFLAMMATORY DISEASES | MAPKAPK5, DUSP5, MAP3K5 | MAPK7 60/4885LRRK2 427/4885BRD4 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.